Wird geladen...
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
BACKGROUND: Severe coronavirus disease 2019 (Covid-19) is associated with dysregulated inflammation. The effects of combination treatment with baricitinib, a Janus kinase inhibitor, plus remdesivir are not known. METHODS: We conducted a double-blind, randomized, placebo-controlled trial evaluating b...
Gespeichert in:
| Veröffentlicht in: | N Engl J Med |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Massachusetts Medical Society
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7745180/ https://ncbi.nlm.nih.gov/pubmed/33306283 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa2031994 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|